Vnitr Lek 2005, 51(5):555-559

Prolonged administration of low-molecular heparins in the prophylaxis of postoperative thrombosis

M. Čepelák
I. interní klinika Lékařské fakulty UK a FN Plzeň, přednosta prof. MUDr. Karel Opatrný jr., DrSc.

Low-molecular-heparins have become a standard medication of venous thrombosis prevention in orthopaedic and general surgery. Reasons for extended prophylaxis with low-molecular heparins after hospital discharge are best evident in patients with total hip replacement. In this patient group a high incidence of thromboembolic complications in the late period after surgery has been ascertained and the origin of new asymptomatic thrombosis cases has been documented by phlebography and duplex sonography. A prolonged treatment with low-molecular heparins leads to a significant lowering of the frequency of manifest as well as asymptomatic thrombosis and finds application in other indications of thrombosis prophylaxis as well.

Keywords: low-molecular heparins; preventionpostoperative thrombosis; total hip replacement; thromboembolic complications

Received: March 3, 2004; Accepted: August 31, 2004; Published: May 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čepelák M. Prolonged administration of low-molecular heparins in the prophylaxis of postoperative thrombosis. Vnitr Lek. 2005;51(5):555-559.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arnold MD, Kahn RS, Shrier I. Missed opportunities for prevention of venous thromboembolism. An evaluation of the use of thromboprophylaxis guidelines. Chest 2001; 120: 1964-1971. Go to original source... Go to PubMed...
    2. Bergqvist D, Agnelli G, Cohen TA et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346(13): 975-979. Go to original source... Go to PubMed...
    3. Bergqvist D, Lowe G. Venous thromboembolism in patients undergoing laparoscopic and arthroscopic surgery and in leg casts. Arch Intern Med 2002; 162: 2173-2176. Go to original source... Go to PubMed...
    4. Clagett GP, Anderson FA, Geerts WH et al. Prevention of venous thromboembolism. Chest 1998; 114: 531S-560S. Go to original source... Go to PubMed...
    5. Dahl OE, Andreassen G, Aspelin T. Prolonged thromboprophylaxis following hip replacement surgery - results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin. Thromb Haemost 1997; 77: 26-31. Go to original source... Go to PubMed...
    6. Dulíček P, Pavlata J, Karpaš K et al. Profylaxe tromboembolické nemoci po náhradě kyčelního kloubu. Acta Chir Orthop Traumatol Čechosl 2000; 67: 243-245.
    7. Eriksson IB. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Thromb Res 2003; 109: S23-S29. Go to original source... Go to PubMed...
    8. Eriksson IB, Bergqvist D, Kalebo I et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-1447. Go to original source... Go to PubMed...
    9. Eriksson IB, Lassen RM. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery. Arch Intern Med 2003; 163: 1337-1342. Go to original source... Go to PubMed...
    10. Eriksson IB, Orgren M, Eriksson GU et al. Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. Thromb Res 2002; 105: 371-378. Go to original source... Go to PubMed...
    11. Francis WC, Berkowitz DS, Comp CP. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349(18): 1703-1712. Go to original source... Go to PubMed...
    12. Francis WC, Davidson LB, Berkowitz DS. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. Ann Intern Med 2002; 137: 648-655. Go to original source... Go to PubMed...
    13. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest 2001; 119(Suppl 1): 132S-175S. Go to original source... Go to PubMed...
    14. Haentjens P. Venous thromboembolism after total hip arthroplasty a review of incidence and prevention during hospitalization and after hospital discharge. Acta Orthop Belg 2000; 66(1): 1-8.
    15. Haentjens P, Delincé PH. Prevention of venous thromboembolism after hospital discharge. Hip International 2001; 11(1): 25-36. Go to original source...
    16. Howard WA, Aaron DS. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. Thromb Haemost 1998; 79: 902-906. Go to original source... Go to PubMed...
    17. Hull DR, Pineo FG, Stein DP et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: A systematic review. Ann Intern Med 2001; 135: 858-869. Go to original source... Go to PubMed...
    18. Jorgensen SP, Warming T, Hansen K et al. Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast A venografic controlled study. Thromb Res 2002; 105: 477-480. Go to original source... Go to PubMed...
    19. Koopman MMW, Büller HR. Short- and long-acting pentasaccharides. J Intern Med 2003; 254: 335-342. Go to original source... Go to PubMed...
    20. Kujath P, Spannagel U, Habscheid W. Incidence and prophylaxis of deep venous thrombosis in outpatients with injury of the lower limb. Hamostasis 1993; 23(Suppl 1): 20-26. Go to original source... Go to PubMed...
    21. Lassen RM, Bauer AK, Eriksson IB et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-1720. Go to original source... Go to PubMed...
    22. Lee AYY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153. Go to original source... Go to PubMed...
    23. Menzin J, Colditz AG, Regan MM et al. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995; 155: 757-764. Go to original source...
    24. Nicolaides AN, Bergqvist D, Hull R. Prevention of venous thromboembolism. International consensus statement (Guideline according to scientific evidence). Internat Angiol 1997; 16(1): 3-38.
    25. PERSIST investigators: A novel long-acting synthetic factor Xa inhibitor (SanOrg 34006) to replace warfarin for secondary prevention in venous thrombosis. A phase II evaluation. J Thromb Haemost 2003; 2(1): 47-53. Go to original source... Go to PubMed...
    26. Planes A, Vochelle N, Darmon JY et al. Efficacy and safety of post-discharge administration of enoxaparin in the prevention of venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial. Lancet 1996; 348: 224-228. Go to original source... Go to PubMed...
    27. Roth P. Thromboembolieprophylaxe bei ambulant duchgefuhrten arthroskopischen Meniskusoperationen. Orthop Praxis 1995; 5: 345-348.
    28. Samama MC, Vray M, Barré J et al. Extended venous thromboembolism prophylaxis after total hip replacement. Arch Intern Med 2002; 162: 2191-2196. Go to original source... Go to PubMed...
    29. Schulman S. Unresolved issues in anticoagulant therapy. J Thromb Haemost 2003; 1: 1464-1470. Go to original source... Go to PubMed...
    30. Schulman S, Wahlander K, Lundstrom T et al. Secondary prevention of thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349: 1713-1721. Go to original source... Go to PubMed...
    31. Spannagel U, Kujath P. Low molecular weight heparin for the prevention of thromboembolism in outpatients immobilized by plaster cast. Semin Thromb Hemost 1993; 19(1): 131-141.
    32. Štědrý V. Totální endoprotéza kyčelního kloubu. Doporučený postup ČLS JEP reg. č. a/113/206 2002; 1-8 (www.cls.cz/dp/index.html).
    33. Turpie GGA, Bauer AK, Eriksson IB et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. Arch Intern Med 2002; 162: 1833-1840. Go to original source... Go to PubMed...
    34. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: 1-4. Go to original source... Go to PubMed...
    35. White RH, Romano PS, Zhou H et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998; 158(14): 1525-1531. Go to original source... Go to PubMed...
    36. Zeman J, Dungl P, Fajtová A et al. Zjišťování rizika trombózy dolních končetin po implantaci endoprotézy kyčelního kloubu ve fázi rehabilitace po propuštění z nemocnice. Prakt Flebol 1999; 1: 20-26.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.